 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...

SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who read more...

FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas

SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear...

SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX  Get Free Report) gapped up before the market opened on Tuesday after HC Wainwright raised their price target on the stock from $52.00 to $64.00...

SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up  on Analyst Upgrade

In trading on Tuesday, shares of SpringWorks Therapeutics Inc (SWTX) crossed above their 200 day moving average of 26.35, changing hands as high as 26.87 per share. SpringWorks...

SpringWorks Therapeutics (SWTX) Shares Cross Above 200 DMA

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Springworks Therapeutics (SWTX Research Report), with a price target of $64.00...

Buy Rating Affirmed for Springworks Therapeutics on OGSIVEO's Superior Efficacy and FDA Approval

Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain...

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO  (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX  Get Free Report) shot up 5% during mid-day trading on Friday . The stock traded as high as $21.83 and last traded at $21.75. 183,225 shares changed...

SpringWorks Therapeutics (NASDAQ:SWTX) Shares Up 5%

This indicator may be signaling SWTX's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

SpringWorks Therapeutics (SWTX, $21.75) entered Uptrend as Momentum indicator ascends above 0 level on Nov 24, 2023

SpringWorks Therapeutics (NASDAQ:SWTX  Free Report) had its price objective lowered by HC Wainwright from $58.00 to $52.00 in a research note published on Monday morning, Benzinga reports. The...

SpringWorks Therapeutics (NASDAQ:SWTX) Given New $52.00 Price Target at HC Wainwright

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Watchers	700
52-Wk Low	$18.00
52-Wk High	$34.16

Market Cap	$1.3B
Volume (M)	2.19M
52-Wk High	$34.16
52-Wk Low	$18.00

SWTX SpringWorks Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community